| |
| |
|
| Insider
Information: |
Fair Richard A. |
| Relationship: |
|
| City: |
Houston |
| State: |
TX |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
6,813 |
|
|
Indirect Shares
|
5,000 |
|
|
| Direct
Value |
$509 |
|
|
|
Indirect Value
|
$374 |
|
|
| Total
Shares |
11,813 |
|
|
| Total
Value |
$883 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
1
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
| Percentage
Gain/Loss : |
 -26.6%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Bellicum Pharmaceuticals, Inc |
BLCM |
President and CEO, Dir... |
2020-03-17 |
6,813 |
2020-03-17 |
5,000 |
Premium* |
|
|
Clovis Oncology, Inc. |
CLVS |
|
|
0 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
3 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BLCM |
Bellicum Pharmaceuticals,... |
President and CEO |
• • – |
2020-03-17 |
4 |
B |
$4.00 |
$19,999 |
I/I |
5,000 |
5,000 |
2.58 |
% |
|
| BLCM |
Bellicum Pharmaceuticals,... |
President and CEO |
• • – |
2019-09-10 |
4 |
B |
$1.25 |
$50,000 |
D/D |
40,000 |
66,561 |
2.81 |
- |
|
| BLCM |
Bellicum Pharmaceuticals,... |
President and CEO |
• • – |
2019-08-21 |
4 |
B |
$0.99 |
$19,780 |
D/D |
20,000 |
26,561 |
2.81 |
- |
|
3 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
